




PHARMACEUTICAL 2018

Akebia Therapeutics Inc.
Rank 217 of 342





PHARMACEUTICAL 2018

Akebia Therapeutics Inc.
Rank 217 of 342



The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 42%, being 3.5% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	358,356
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	144,349
Liabilities, Non-Current	22
Other Assets	2,274
Other Compr. Net Income	-400
Other Expenses	0
Other Liabilities	100,545
Other Net Income	180,987
Other Revenues	0
Property and Equipment	3,617
Research and Development	230,893
Selling, General and Administrative Expense	27,008

Output Variable	Value in 1000 USD
Assets	364,247
Liabilities	244,916
Expenses	257,901
Revenues	0
Stockholders Equity	119,331
Net Income	-76,914
Comprehensive Net Income	-77,114
Economic Capital Ratio	42%